The molecular signature that discriminates between the two forms of liver cancer is the expression of proteins involved in lipid metabolism, such as alpha-methylacyl-CoA racemase (AMACR), sterol regulatory element-binding proteins (SREBP), and fatty acid synthase (FASN), that were found enriched in HCC tumors. This evidence concerns the gene AMACR and liver cancer.